The cell engineering and biosecurity specialist's sales slumped as a big source of COVID-related revenue dried up.

After lackluster first-quarter earnings, Ginkgo Bioworks said it will slash labor expenses by at least 25 percent, which will ...

After a disappointing first quarter earnings, Ginkgo Bioworks plans to reduce its labor expenses at least 25%. The company ...

Ginkgo Bioworks (NYSE:DNA) lost ~11% premarket Friday after the cell platform company slashed its full-year revenue outlook, ...

Ginkgo Bioworks' first quarter earnings were weak, with revenue and guidance falling well short of expectations. The company ...

Q1 2024 Earnings Call Transcript May 9, 2024 Ginkgo Bioworks Holdings, Inc. isn’t one of the 30 most popular stocks among ...

Revenue: Reported at $38 million for Q1 2024, a significant decrease of 53% from $81 million in the prior year, falling short ...

Key Insights Significantly high institutional ownership implies Ginkgo Bioworks Holdings' stock price is sensitive ...

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago. These figures are ...

Cathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ...

Ginkgo Bioworks releases earnings for the most recent quarter.Wall Street predict expect Ginkgo Bioworks will release losses per share ...

Enter Ginkgo Bioworks, a company that aims to “make biology easier to engineer.” The company harnesses the power of AI and robotics to automate complex biological tasks. It's a holding in the ...